Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Zsolt Talloczy

Showing results (11-20 of 15) with videos related to

Pageof 2
Sort By:
You have reached the last page of results.This site can display upto 15 results.
Nature Neuroscience|April 13, 2010
Cargo recognition failure is responsible for inefficient autophagy in Huntington's diseaseMarta Martinez-Vicente, Zsolt Talloczy, Esther Wong, et al.
The Lancet. Diabetes & Endocrinology|January 9, 2023
Long-term efficacy and safety of inclisiran in patients with high cardiovascular risk and elevated LDL cholesterol (ORION-3): results from the 4-year open-label extension of the ORION-1 trialKausik K Ray, Roel P T Troquay, Frank L J Visseren, et al.
Cardiovascular Research|May 16, 2024
Inclisiran administration potently and durably lowers LDL-C over an extended-term follow-up: the ORION-8 trialR Scott Wright, Frederick J Raal, Wolfgang Koenig, et al.
The Journal of Neuroscience : the Official Journal of the Society for Neuroscience|February 11, 2011
Akt suppresses retrograde degeneration of dopaminergic axons by inhibition of macroautophagyHsiao-Chun Cheng, Sang Ryong Kim, Tinmarla F Oo, et al.
The Journal of Clinical Investigation|January 4, 2008
Dopamine-modified alpha-synuclein blocks chaperone-mediated autophagyMarta Martinez-Vicente, Zsolt Talloczy, Susmita Kaushik, et al.
Pageof 2

Showing results (11-20 of 15) with videos related to

Sort By:
Pageof 2
You have reached the last page of results.This site can display upto 15 results.
Nature Neuroscience|April 13, 2010
Cargo recognition failure is responsible for inefficient autophagy in Huntington's diseaseMarta Martinez-Vicente, Zsolt Talloczy, Esther Wong, et al.
The Lancet. Diabetes & Endocrinology|January 9, 2023
Long-term efficacy and safety of inclisiran in patients with high cardiovascular risk and elevated LDL cholesterol (ORION-3): results from the 4-year open-label extension of the ORION-1 trialKausik K Ray, Roel P T Troquay, Frank L J Visseren, et al.
Cardiovascular Research|May 16, 2024
Inclisiran administration potently and durably lowers LDL-C over an extended-term follow-up: the ORION-8 trialR Scott Wright, Frederick J Raal, Wolfgang Koenig, et al.
The Journal of Neuroscience : the Official Journal of the Society for Neuroscience|February 11, 2011
Akt suppresses retrograde degeneration of dopaminergic axons by inhibition of macroautophagyHsiao-Chun Cheng, Sang Ryong Kim, Tinmarla F Oo, et al.
The Journal of Clinical Investigation|January 4, 2008
Dopamine-modified alpha-synuclein blocks chaperone-mediated autophagyMarta Martinez-Vicente, Zsolt Talloczy, Susmita Kaushik, et al.
Pageof 2